FDA
-
-
-
-
-
-
-
Pre-Open Stock Movers 06/05: (HTZ) (QEP) (AAL) Higher; (WORK) (MNLO) (PD) Lower (more...)
-
-
-
-
-
-
-
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) Announces Covered Status for AMZEEQ topical foam, 4%, on Additional Commercial Formulary
-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) Phase 3 Study MTI-105 and Study MTI-106 did not meet their respective primary endpoint
-
-
-
-
-
-
-
Menlo Therapeutics Provides a Business Update in the Context of COVID-19
-
-
-
-
-
-
-
Pre-Open Movers 11/11: (CARB) (SPWR) (WBA) Higher; (LPCN) (NXTC) (FOMX) Lower (more...)
-
-
-
-
-
-
-
Menlo Therapeutics (MNLO) Reports Complete Patient Enrollment in Two Ph. 3 Trials of Serlopitant in Prurigo Nodularis
-
322,233 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

